Antiseptic agents are increasingly used for hand hygiene and skin decolonization as key tools for the prevention of healthcare-associated infections. Chlorhexidine, a divalent, cationic biguanide, has a broad spectrum of activity and is one of the most frequently used topical antiseptic agents. Notably, there are an increasing number of prevalence studies that report reduced levels of susceptibility to chlorhexidine. In contrast to bacterial resistance to antibiotics, using parameters such as the MIC to define resistance to antiseptics, including chlorhexidine, is not straightforward. A range of methods have been used for the detection of reduced susceptibility to chlorhexidine, but, importantly, there is no standardized method and no consensus on the definition of chlorhexidine 'resistance'. In this review we have assessed the methods available for the detection of reduced susceptibility to chlorhexidine and the prevalence of coresistance to other antimicrobial agents. We have focused on the development of reduced susceptibility to chlorhexidine and the presence of efflux-mediated resistance genes in staphylococci, and have reviewed the clinical significance of this phenomenon. Lastly, we have identified unanswered questions to further our understanding of this emergent threat. We anticipate that clinical use of chlorhexidine will continue to increase, and it will be important to be alert to the possibility that this may lead to the emergence of new clones with reduced susceptibility. Indiscriminate chlorhexidine use in the absence of efficacy data should be discouraged.
Introduction
Over the past decade, there has been considerable focus on the prevention of healthcare-associated infections (HCAIs), including those caused by methicillin-resistant Staphylococcus aureus (MRSA). One of the cornerstones of preventative measures has been the use of antiseptic agents for hand hygiene and skin decolonization prior to invasive procedures. Due to its broad spectrum of activity, acceptable tolerability and good safety record, chlorhexidine is one of the most frequently used antiseptic agents, or biocides. 1 Consequently, there is a plethora of information available about chlorhexidine and its application for the prevention of S. aureus infections, in particular those caused by MRSA. The decreased availability of triclosan products following concerns about safety 2 and selection of antimicrobial resistance 3 has exacerbated the increasing exposure to chlorhexidine. Furthermore, there is increasing attention on the control of methicillin-susceptible S. aureus (MSSA), which will likely include further use of chlorhexidine-containing products. 4, 5 Not surprisingly, therefore, there are an increasing number of prevalence studies that report reduced levels of susceptibility to chlorhexidine, with emphasis on the susceptibility of MRSA. Importantly, a range of methods have been used for the detection of reduced susceptibility to chlorhexidine, but there is no standardized method and no consensus on the definition of chlorhexidine 'resistance'. Notably, many investigations of the mechanisms of chlorhexidine resistance include only Gramnegative organisms 6, 7 and chlorhexidine may not be included in the panel of antiseptics tested. 8 -10 There are a number of thorough reviews on bacterial resistance to biocides; however, these provide an overview of all biocides and include Grampositive and -negative bacteria. 11 -14 In addition, the Scientific Committee on Emerging and Newly Identified Health Risks have produced a report that assesses the antibiotic resistance effects of biocides. 15 In contrast, we have reviewed the evidence for reduced susceptibility to chlorhexidine in staphylococci. We begin with a brief description of chlorhexidine, and a summary of its uses, benefits and disadvantages. We then focus on the development of reduced susceptibility to chlorhexidine in staphylococci, along with the presence of efflux-mediated resistance genes and the prevalence of coresistance. We conclude by posing questions that remain to be answered. divalent, cationic biguanide agent that exists as gluconate, acetate and hydrochloride salts. 17 Chlorhexidine is most commonly used at various concentrations (0.5%-4%) of the watersoluble gluconate form. 18 Chlorhexidine acts by binding to the negatively charged bacterial cell wall and affecting the osmotic equilibrium of the cell. 19 Briefly, the biguanide groups of the chlorhexidine molecules bind strongly to exposed anionic sites on the cell membrane and cell wall. The formation of bridges between adjacent phospholipid head groups displaces the divalent cations (Mg 2+ and Ca 2+ ) that naturally stabilize the cell membrane, and as a result the cell membrane becomes leaky to potassium ions and protons. 20 At higher, in-use, concentrations, binding of chlorhexidine causes the membrane to lose structural integrity, which results in cell death. 17 Further details about the mechanism of action of chlorhexidine, and other antiseptics, can be found in an article by Gilbert and Moore. 20 Chlorhexidine is most active against Gram-positive bacteria, but also has activity against Gram-negative bacteria, anaerobes, fungi and some enveloped viruses. 19, 21, 22 Evidence of chlorhexidine activity against mycobacteria is inconclusive and it has limited activity against non-enveloped viruses. 1 The agent is not active against bacterial spores.
1 Chlorhexidine is known to be less effective in the presence of organic material, such as serum. 23 
Uses and benefits of chlorhexidine
Hand hygiene is acknowledged to be one of the key elements of effective infection prevention and control in healthcare facilities, as multiresistant organisms, such as MRSA, are known to be transmitted between patients via hands. 24 The WHO recommends the use of alcohol-based hand rubs as 'the gold standard for hand hygiene in health care'. 25 Alcohol-based hand rubs may contain additional active ingredients, such as chlorhexidine, but the inclusion of such agents is not essential.
Chlorhexidine effectively reduces numbers of bacterial skin flora 26 and is available for use in aqueous form, combined with 70% isopropyl alcohol or as a dusting powder, depending on the application. 27 Chlorhexidine has been used in preparations for hand cleansing, both general and pre-surgical, for .50 years. 18, 26 Equally important is its use in skin disinfection prior to surgical procedures and the insertion of peripheral and central vascular catheters. Guidelines recommend the use of 2% chlorhexidine gluconate in 70% isopropyl alcohol solution for skin preparation before catheter insertion. 28 -30 Screening for carriage of MRSA followed by decolonization of colonized individuals has been a widespread strategy for the prevention and control of MRSA in hospitals. Decolonization usually consists of the application of a topical antibiotic, such as mupirocin, to the anterior nares and bathing with an antiseptic-containing body wash, 26, 31 with chlorhexidine being the most frequently used antiseptic-containing body wash. In recent years, chlorhexidine has been used in more novel ways in order to prevent HCAIs, including vascular catheter-related infections and ventilatoracquired pneumonia. Table 1 summarizes the breadth of chlorhexidine use in healthcare settings.
As well as a broad range of activity, a key potential advantage of chlorhexidine, especially when used as a skin disinfectant, is its 'residual activity'. 24, 26 When compared with povidone iodine, chlorhexidine not only produces a greater reduction in the skin flora, 32 it also has longer residual activity. 33 Measurements of the efficacy and potential residual activity of chlorhexidine are dependent on the removal or neutralization of chlorhexidine after the defined point of exposure. 15 If a validated neutralization step is not included in the test procedure, the efficacy of chlorhexidine may be overestimated, as the biocide may continue to cause damage to cells after exposure. 34, 35 The inclusion of a valid neutralizing step is missing from many published studies, leading some authors to challenge the data demonstrating the residual potency of chlorhexidine, specifically relating to hygienic hand disinfection. 34 A potential source of false elevation of MICs is if bacteria are not adequately dispersed in vitro, in effect partially simulating a biofilm mode of growth.
The safety and tolerability of chlorhexidine is good. 36 It is less likely to cause dry skin than non-medicated soap 22 and in one study it caused less dermatitis of the hands of nurses than soaps containing other antiseptic agents. 37 Irritation of the skin and allergic reactions, such as dermatitis, are more likely at higher concentrations, but are relatively uncommon. There Review are rare cases of severe side effects, such as anaphylaxis 38 and ototoxicity if applied to the inner ear. 39 The use of chlorhexidine in babies ,2 months old is not advised, in part because of concerns about the systemic absorption of the agent and the potential for neurotoxicity. 40 Reduced susceptibility to chlorhexidine Bacteria may be described as insusceptible, phenotypically tolerant, tolerant or resistant to antiseptics ( Table 2) . As with antibiotic agents, resistance to antiseptics can be either intrinsic or acquired. Intrinsic resistance, or insusceptibility, to chlorhexidine is demonstrated by bacterial spores and mycobacteria. In both cases the outer layers of the cell form an impermeable barrier to the ingress of molecules. 1 In Gram-negative bacteria, such as Proteus and Providencia species, intrinsic properties of the outer membrane also confer resistance to chlorhexidine at in-use concentrations. 41 Phenotypic tolerance refers to the survival of a microorganism in the presence of a biocide during specific growth conditions, such as the 'protective' setting of a biofilm.
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Once removed from the biofilm, the organism generally returns to a susceptible phenotype. 11 Efflux pumps are common mechanisms of resistance to antiseptics, such as chlorhexidine. 12, 42, 43 Efflux pumps are energy dependent, powered by ATP or the proton-motive force (PMF), and have the capacity to remove both antiseptics and antibiotics according to their substrate range. Efflux is the primary mechanism of reduced susceptibility to chlorhexidine in S. aureus.
14 Both Gram-negative and -positive bacteria can acquire genes encoding efflux pumps, which are commonly present on mobile genetic elements. While intrinsic resistance/insusceptibility and phenotypic tolerance are reasonably easy to define, the same cannot be said for chlorhexidine 'resistance'.
Bacterial resistance to antibiotics is generally clear and readily defined, using parameters such as the MIC; however, resistance measured in these terms is of less relevance to antiseptics, including chlorhexidine, for several reasons. Firstly, lethal rather than inhibitory effects are more important. 41 In vitro, bacteria are tested against much lower concentrations of biocide (i.e. in the case of chlorhexidine, 4 mg/L) and bacterial survival at an MIC concentration, such as 4 -32 mg/L, does not necessarily guarantee bacterial survival at the much higher concentrations that are achieved in practice (i.e. 40 000 mg/L in 4% aqueous chlorhexidine solution). 44 For this reason, the use of time -kill tests and measurement of MBC may be more appropriate. 6 Also, both the MIC and MBC relate to specific concentrations attainable in body fluids (e.g. serum and urine), which are not relevant to antiseptics. 43 In the purest sense, MIC values indicate tolerance to chlorhexidine rather than resistance; however, chlorhexidine 'resistance' has been used extensively in the literature to date. When bacteria are able to survive at in-use concentrations of a biocide, noting that these vary considerably according to the application/product (Table 1) , the bacteria may be defined as resistant; however, when tested at lower concentrations in vitro, the bacteria should be considered tolerant to the biocide. 12 Taking these issues into consideration, our preferred term for phenotypic 'resistance' is 'reduced susceptibility' to chlorhexidine, whereas genotypic resistance could be described as the presence of efflux-mediated resistance genes.
Phenotypic detection of reduced susceptibility to chlorhexidine
Susceptibility to chlorhexidine is commonly tested using phenotypic and MIC-or MBC-based, methods. MIC methods measure the lowest possible concentration of a biocide that will inhibit growth of the organism, whereas an MBC method measures the lowest possible concentration required to kill the organism. 45 In staphylococci, chlorhexidine resistance is often defined as an MIC ≥4 mg/L, 46 -48 although, as discussed, this may be more accurately described as reduced susceptibility to chlorhexidine. Crucially, a standardized method for chlorhexidine MIC determination is not available 47 and some authors do not consider MIC-based methods to be suitable for measuring the susceptibility of bacteria to chlorhexidine. 44, 49 Alternative methods of chlorhexidine assessment have been used, such as surface disinfection tests and biocide residue tests. 49 Chlorhexidine has a low diffusion rate through solid agar and, thus, is not suited to susceptibility testing methods based on disc diffusion. 50 Table 3 summarizes the methods that have been used to test the phenotypic susceptibility of staphylococci to chlorhexidine.
It has been suggested that the method used for phenotypic susceptibility testing should mimic the in-use conditions as closely as possible. 6 Bacteria are not likely to achieve optimal growth in vivo, due to environmental stresses, such as lack of available nutrients, whereas in vitro bacteria are encouraged to grow and inocula are generated using nutrient-rich media. The results of phenotypic biocide susceptibility testing may be affected by the experimental conditions used, such as the culture media, inoculum size and age of the culture, as reviewed Table 2 . Possible outcomes of an interaction of bacteria with chlorhexidine 11, 12, 43 Term Definition
Intrinsic resistance/insusceptible bacteria that are intrinsically resistant to chlorhexidine, such as mycobacteria or bacterial spores Phenotypic tolerance survival in the presence of chlorhexidine due to low metabolism or due to a transient condition, such as the presence of a biofilm Chlorhexidine tolerance a bacterial strain that is inhibited but not killed by chlorhexidine, such as exposure to bacteriostatic concentrations of chlorhexidine used in vitro (4 mg/L) Chlorhexidine resistance a bacterial strain that can survive exposure to chlorhexidine at a concentration that kills the rest of the bacterial population, such as the in-use bactericidal concentration of chlorhexidine (40 000 12 For instance, when staphylococci were grown in suspension, lower amounts of the biocides tested (benzalkonium chloride/chlorhexidine digluconate) were taken up by cells compared with when staphylococci were grown on agar; as such, staphylococci grown in broth may appear susceptible, while agar-cultured strains appear resistant. 51 The presence of organic matter, biofilms and biocide residues at sublethal concentrations are additional factors that need to be taken into account when comparing the in vitro and in vivo susceptibility of biocides. These factors may contribute to the survival of a subpopulation of bacterial cells in the presence of a particular biocide, compared with the majority of cells that will remain susceptible. The concept of heterogeneous resistance to chlorhexidine, defined as the presence of subpopulations of staphylococci that can survive at in-use concentrations of the agent, is a plausible one, given that heteroresistance to vancomycin is observed in some populations of S. aureus; 52 however, information about heterogeneous susceptibility to chlorhexidine in staphylococci is non-existent.
In summary, the results of phenotypic susceptibility testing are highly dependent on the method used and there are no nationally/internationally agreed breakpoint values for biocide susceptibility testing, which makes it difficult to standardize research in the field, and indeed to interpret the significance of results from published studies.
Chlorhexidine resistance genes
Phenotypic methods are a valuable way to screen isolates directly for chlorhexidine susceptibility; however, confirmation of the presence of DNA sequences known to encode efflux-mediated chlorhexidine resistance genes is an alternative method to identify specific mechanisms.
Currently, there are ≥11 genes known to encode effluxmediated resistance to biocides (qacA, B, E, ED1, F, G, H, J, Z, smr and norA) (Table 4) ; however, not all of the 11 resistance genes have been identified in staphylococci. The genes can be categorized into two families, the major facilitator superfamily (MFS) and the small multidrug resistance (SMR) family, according to DNA homology, protein structure, substrate specificity and plasmid association of the proteins they encode. Proteins of both families encode efflux-mediated resistance to a range of structurally unrelated cationic, lipophilic substrates across the cell membrane, powered by the PMF. 42, 53 In general, the MFS family encodes resistance to biocides, including chlorhexidine, whereas the SMR family confers resistance to certain biocides but not chlorhexidine. Staphylococci have the capacity to efflux lipophilic cations, such as quaternary ammonium compounds, intercalating dyes, diamidines and biguanidine compounds, including chlorhexidine. In fact, the substrate range for QacA comprises 30 cationic lipophilic compounds distributed across 11 chemical classes. 54 The qacA gene in S. aureus was the first gene encoding a PMF-dependent efflux system to be sequenced and described. 55 -57 The QacA and QacB proteins, which belong to the MFS family 1, are large proteins known to have 14 membrane-spanning regions. Conserved sequences are found in the N-terminal region of the protein, likely to be involved in the generation of energy to transport molecules, whereas the C-terminal region contains variable sequences responsible for substrate specificity. Of note, there are seven nucleotide differences present in the sequence of qacB compared with qacA. These nucleotide differences result in a single amino-acid substitution from Asp to Ala at codon 323. Subsequently, qacB is not able to efflux divalent cations.
Of the 11 known biocide resistance genes, qacA is the gene that is commonly associated with reduced susceptibility to chlorhexidine in staphylococci. Although the majority of the 'wild-type' genes are not strictly able to efflux chlorhexidine in their native state (Table 4) , there are examples of qac genes that occasionally encode phenotypic reduced susceptibility to incorporation of different concentrations of chlorhexidine into nutrient agar followed by the application of a controlled number of bacterial cells to the surface of the agar five or more doubling dilution concentrations are used and an MIC value can be determined chlorhexidine may be tested at specific concentrations necessary for differentiation of susceptible, intermediate or resistance isolates (breakpoint agar method) a multipoint or spiral plate method can be used microbial contamination and heterogeneity are easily detected chlorhexidine has a low diffusion rate through solid agar MIC by broth dilution 48, 61, 62 serial dilution of chlorhexidine into broth and addition of a controlled number of bacterial cells macrodilution method (i.e. large volumes of broth in tubes) or microdilution method (i.e. small volumes in the wells of a microtitre plate) can be readily converted to the MBC test; an appropriate neutralization step must be included other substances can be added to the broth if necessary (i.e. neutralizer) MBC by broth dilution 74 as MIC by broth dilution, including neutralization, followed by inoculation of solid biocide-free agar with an aliquot from the broth Time-kill study 80 the measurement of growth of bacteria exposed to a biocide in broth for different lengths of time (h) the study of inactivation kinetics can provide useful information about clonal populations and aggregation depending on the shape of the resultant inactivation kinetic Review chlorhexidine. For instance, isolates of coagulase-negative staphylococci found to carry only qacC (now known as smr), a gene that does not usually encode phenotypic reduced susceptibility to chlorhexidine, exhibited chlorhexidine MICs .4 mg/L. 58 These raised MICs may be due to the presence of base-pair mutations in the qacC gene that cause a change in substrate specificity or there may be another undetected mechanism of resistance, i.e. overexpression of norA can also produce a similar resistance phenotype. 42 These instances justify the importance of surveillance for other qac genes, not just qacA.
The presence of qacA does not necessarily mean that an isolate will express phenotypic resistance to chlorhexidine. Staphylococci may appear susceptible despite the presence of qacA; conversely, efflux-mediated resistance gene(s) may be absent but the bacteria may display reduced susceptibility to chlorhexidine (Table 5) . One way to investigate this variability further would be to measure RNA expression of chlorhexidine resistance genes during exposure to the agent. Two studies that have used this approach include an investigation of the molecular mechanisms of chlorhexidine tolerance in Listeria monocytogenes 59 and in Burkholderia cenocepacia biofilms. 60 Staphylococci may carry more than one biocide effluxmediated resistance gene that confers resistance to a similar range of substrates (Table 5) . 10, 61, 62 A possible selective advantage of this phenomenon may relate to the fact that qacA encodes resistance to the widest range of biocides, whereas other genes (e.g. smr), although not enabling the same level of resistance to biocides, may be associated with resistance to other antibiotic agents or additional mobile genetic elements, so increasing the chance of microbe survival. 62 Biocide resistance genes are part of tightly regulated virulence systems. In addition to the presence of single genes encoding chlorhexidine resistance, the wider effects of global regulatory systems may result in an efflux-based resistance phenotype. 63, 64 Relationship between chlorhexidine resistance genes and other antimicrobial resistance genes in staphylococci
In addition to reduced susceptibility to chlorhexidine and other biocides, the presence of biocide efflux-mediated resistance genes in staphylococci also has implications for other antimicrobial agents in terms of cross-resistance and coresistance. For instance, the multidrug efflux pump encoded by norA is capable of removing biocides and fluoroquinolones. 63 On the other hand, coresistance occurs because of the shared location of chlorhexidine resistance genes on the same mobile genetic elements as other antimicrobial resistance genes.
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The qacA gene was first described from a plasmid that encoded resistance to heavy metals and b-lactam agents (Tn4002). 65 Other transmissible plasmids that qacA has been found associated with include pSK1, pSK105, pSK107, pSK4032, pSK4769, pSK638 and pSK57. 58 Each family of plasmids is known to carry resistance to other antibiotics, such as aminoglycosides (Tn4001) and trimethoprim (Tn4003). 55 The qacA/B genes have been identified in MRSA strains carrying SCCmec types I -V, most commonly types II and III. 47, 66 Various plasmids (e.g. PuB110 and pT181) and transposons (i.e. Tn554, Tn4001 and Tn5801) can be found integrated into certain allotypes of the SCCmec element (types I, II, III, IVa and IVc), and staphylococci encoding these SCCmec types will carry additional antibiotic resistance genes, in particular coding for resistance to aminoglycosides, tetracycline and the macrolide -lincosamidestreptogramin group. 67 Genetic linkage between the qacA/B genes and b-lactamase resistance mediated by blaZ has been reported; 47 an association that has been noted in both S. aureus and coagulase-negative staphylococci. 68 Associations between chlorhexidine resistance genes and resistance to other antibiotic classes have also been 62 Such associations could simply reflect the copresence/absence of resistance genes that are subject to selection pressures, some of which may overlap with those for chlorhexidine resistance mechanisms.
Whether the presence of genes that encode efflux-mediated resistance to chlorhexidine selects for the presence of antibiotic resistance genes is a well-debated question. 11, 43 When the prevalence of antiseptic resistance genes in staphylococci was compared between nurses and the general population, a higher incidence of qac genes was identified in staphylococci that were colonizing hospital nursing staff compared with staphylococci from the general population. 62 This result may indicate that the use of biocides in the hospital setting could select for strains that are able to survive in the presence of biocides.
Prevalence of chlorhexidine resistance genes in staphylococci
The reported prevalence of qac and smr genes in staphylococci varies according to geographical location, ranging from 1% in the eastern states of the USA 69 to 80% in Brazil. 70 Table 6 summarizes the findings of 18 studies that describe the geographical distribution of phenotypic and/or genotypic chlorhexidine resistance. Two studies include the prevalence of other genes that may be associated with chlorhexidine resistance genes, such as norA/blaZ. 49, 71 Four studies compare the association between chlorhexidine resistance genes and methicillin resistance, 10, 46, 62, 72 and four studies investigate the prevalence of chlorhexidine resistance genes in coagulase-negative staphylococci. 10, 58, 62, 71 As mentioned above, there is only one study that compared the prevalence of chlorhexidine resistance genes between healthcare workers and the general population. 62 While the number of studies investigating the prevalence of chlorhexidine resistance genes and reduced susceptibility to chlorhexidine in staphylococci has increased, a definitive conclusion about whether the prevalence of resistance genes and/or the proportion of staphylococci with reduced susceptibility are changing cannot be made. Also, geographical differences in the prevalence of chlorhexidine resistance genes are likely to be the result of numerous factors, such as clonal spread, the population/case mix under study, differences in infection control policies and, potentially, the pressure of use of chlorhexidine. Notably, a lack of consensus regarding chlorhexidine susceptibility testing methodology adds further confusion.
Clonal association of chlorhexidine resistance genes in staphylococci
The clonal predominance of particular strains of staphylococci likely influences the prevalence of chlorhexidine resistance genes. 9, 46 Hence, choice of locale, period of study and isolate selection are key considerations when interpreting such data. Clonal expansion of a single MRSA clone was responsible for the spread of qacA/B resistance genes in a single centre in Japan (1993 -2001) . Of 522 clinical isolates of S. aureus, 109 MRSA isolates were positive for qacA/B genes, compared with 14 MSSA isolates. The MRSA isolates represented 11 spa types, with one spa type (S10) accounting for 38% of qacA/B-positive MRSA isolates. 46 There is also circumstantial evidence of horizontal transfer of plasmids carrying the qacA/B genes among strains of S. aureus and other staphylococci, 66 and transfer of plasmids encoding qacB has been demonstrated in vitro between strains of S. aureus. 73 From a collection of 334 MRSA isolates from patients present on two intensive care unit (ICU) wards in a single institute in Canada between 2005 and 2009, 88 (26%) isolates were identified to harbour qacA/B or smr genes and these isolates were genotyped using spa typing. Seventeen spa types were identified, with two being prevalent (t002 and t008). The qacA/B genes were associated with two spa types from MRSA typically associated with healthcare (t002 and t037), whereas smr genes were associated with more spa types (t002, t007, t008 and t064). 74 Surveillance of 240 isolates from a single hospital in Taiwan over four periods (1990, 1995, 2000 and 2005) showed that the number of lineages with reduced susceptibility to chlorhexidine increased over the study period (one in 1995 to six in 2005). 48 In 1990, no qacA genes were identified in the three dominant lineages [ST254, n¼ 27; ST30, n¼ 22; and ST239, n¼ 10 (where ST stands for sequence type)], although a single isolate of ST239 displayed reduced susceptibility (≥4 mg/L) to chlorhexidine. In 1995, isolates of ST239 and ST254 were still circulating along with two additional lineages, ST59 and ST241. Reduced susceptibility was identified in 1/5 isolates of ST59 and 29/33 isolates of ST241; however, the qacA gene was only identified in 16 of the ST241 isolates. In 2000, a higher number of lineages (n¼ 6) were circulating that had reduced susceptibility to chlorhexidine (ST1, ST5, ST59, ST239, ST241 and ST254). In 2005, there were eight different lineages circulating, with four having reduced susceptibility to chlorhexidine. Since 1990, five lineages (ST1, ST59, ST239, ST241 and ST594) were associated with qacA genes or reduced susceptibility to chlorhexidine. The increase in the prevalence of lineages may be due to increased chlorhexidine use in the area or some other factor. 48 In a separate study, 11 multilocus STs were identified among 206 MRSA isolates from multiple hospitals in Taiwan between 1998 and 2004. 47 Four lineages carried qacA genes (ST239, ST241, ST338 and ST573), whereas isolates of ST5 carried the qacB gene and exhibited reduced susceptibility to chlorhexidine (MIC ≥4 mg/L). MRSA lineages ST1, ST6, ST8, ST59, ST89 and ST900 were also circulating, all of which exhibited reduced susceptibility to chlorhexidine but did not carry qac genes. In conclusion, ST239 is a prevalent MRSA lineage that has been associated with reduced susceptibility to chlorhexidine and carriage of chlorhexidine resistance genes.
Only one study specifically examined examples of healthcare-associated (HA) MRSA, community-associated (CA) MRSA and vancomycin-intermediate S. aureus (VISA) strains, and tested for an association with chlorhexidine resistance genes. 75 qacA genes were identified in 10/38 (26%) HA-MRSA strains and 4/6 (67%) VISA strains, i.e. strains that are likely to have been subjected to selection pressures in the hospital setting. None of the strains of CA-MRSA (n¼ 25) or MSSA (n¼ 25) tested were positive for qacA genes and these isolates had significantly lower chlorhexidine MBCs. The epidemic strain of MRSA in the UK remains EMRSA-15 (ST22-IV) and although it is possible for this strain to carry qacA genes, 49 these genes do not appear to be prevalent in this lineage. 76 Therefore, EMRSA-15 has been a successful lineage in the UK for many years, but without the widespread addition of chlorhexidine resistance genes. On the other hand, rates of MRSA bacteraemia associated with the other predominant MRSA lineage in the UK, EMRSA-16 (ST30-II), have been decreasing, 77 and yet chlorhexidine and mupirocin resistance was commonly found in isolates of this clone in one study. 49 Why chlorhexidine resistance genes may be prevalent in specific lineages is not known, but may be related to plasmid carriage, and the compatibility and transmissibility of mobile genetic elements.
Significance of reduced susceptibility to chlorhexidine in staphylococci
There have been a number of reports that MRSA is less susceptible to chlorhexidine than MSSA. 50, 75, 78, 79 This observation is of particular concern given the widespread use of chlorhexidine for the purposes of MRSA decolonization. Although MRSA may be associated with higher chlorhexidine MICs/MBCs than MSSA, the clinical relevance of this finding has not been fully established. The concentrations of chlorhexidine achieved when used as recommended by the manufacturer are several orders of magnitude greater than the MIC and MBC tested in vitro. 75 It has been shown that chlorhexidine remains effective at killing S. aureus that have an elevated MIC under in vivo experimental conditions. 80 In addition, several authors have shown that repeatedly exposing MRSA to subinhibitory concentrations of chlorhexidine in vitro leads to an increasing level of resistance, as measured by a rise in the MIC. 49, 50, 75 Block and Furman 81 found a significant inverse correlation between the intensity of chlorhexidine use and the overall susceptibility of a group of study bacteria, including S. aureus; however, the results were not significant when species were considered individually. Wang et al. 48 showed that in a Taiwanese hospital, where 4% chlorhexidine had been in use for hand hygiene for .20 years, the proportion of MRSA isolates with a chlorhexidine MIC ≥4 mg/L increased from 1.7% in 1990 to 46.7% in 2005. If extrapolated to the healthcare environment, the residual activity of chlorhexidine after being applied to the skin or an inanimate surface may promote resistance in resident flora. For instance, the prevalence of the qacA/B genes in coagulase-negative staphylococci varies between 12% and 49%, 10, 58, 71 and was found to be higher in isolates from nurses compared with those from the general population (57% versus 14%, respectively; P,0.001). 62 Thus, exposure to chlorhexidine in the hospital environment may select for colonization by chlorhexidine-resistant staphylococci. Given the variety of chlorhexidine-containing products and the concentrations of chlorhexidine in clinical use (0.5%-4%), the consequence of the use of lower concentrations of chlorhexidine in terms of selection of staphylococci with reduced susceptibility requires further investigation.
Review
Notably, the results of two recent studies suggest that reduced susceptibility to chlorhexidine in MRSA may have a clinical impact. Firstly, Batra et al. 82 showed that the use of a chlorhexidine-based surface antiseptic protocol in an ICU led to the spread of an MRSA strain with an elevated MBC to the agent. Secondly, the presence of genotypic chlorhexidine resistance (qacA/B genes) in combination with mupirocin resistance independently predicted failure of MRSA decolonization in a study by Lee et al. 76 Batra et al. 82 aimed to assess the effects of three infection prevention interventions on the rates of MRSA transmission on two 15 bed ICU wards in St Thomas' Hospital, London, between January 2002 and April 2006. At the time of the study, EMRSA-15 (ST22-IV) and EMRSA-16 (ST30-III) were circulating in both units. In addition, both units had been affected by a 2 year outbreak with a non-endemic strain (ST239), which was also recorded during the study period. The interventions were as follows: Intervention A, introduced in July 2003, was based on staff education and covert audit of hand hygiene and barrier nursing practice; Intervention B, introduced in October 2003, involved nursing MRSA-colonized patients in cohorts or side rooms; and Intervention C, introduced in April 2004, was based on the use of a chlorhexidine-based antiseptic for the decolonization of patients colonized with MRSA. Importantly, the concurrent application of mupirocin for decolonization was not included in the third intervention. There was no reduction in MRSA acquisition of ST22 or ST30 strains on the units following intervention A or B; however, following intervention C, numbers of ST22 and ST30 (but not ST239) decreased. Twenty-one ST239 isolates were selected for further investigation; all 21 carried qacA/B genes and had chlorhexidine MBC values that were 3-fold higher than the chlorhexidine MBC values for the 21 non-ST239 isolates that were tested for comparison (78+4 mg/L versus 26+8 mg/L). Only one non-ST239 isolate carried qacA/B genes. Batra et al. 82 concluded that although the use of chlorhexidine antisepsis for MRSA decolonization can lead to an immediate and sustained reduction in the transmission of susceptible strains, caution must be taken in the use of such a protocol in areas where strains with reduced susceptibility to chlorhexidine are circulating. These observations are particularly useful, because mupirocin was not included in the decolonization regimen due to concerns about resistance.
Lee et al. 76 found that the presence of qacA/B genes in combination with mupirocin resistance independently predicted failure of MRSA decolonization. The study took place in a large single centre in Geneva that implemented the use of intranasal mupirocin and chlorhexidine bathing to decolonize MRSA carriers in 1994. Mupirocin resistance increased between 1999 (9%) and 2008 (81%), and by 2008 .99% MRSA isolates had low-level resistance to mupirocin (MIC 8-256 mg/L). The study identified low-level mupirocin resistance in 49/75 (65%) cases versus 26/ 75 (35%) controls prior to decolonization (P,0.001); carriage of qacA/B genes was associated with 68 (91%) cases and 51 (68%) controls (P,0.001). Forty-seven (63%) of the mupirocinresistant isolates carried qacA/B genes. Low-level mupirocin resistance and genotypic chlorhexidine resistance were strongly associated with persistent MRSA colonization after decolonization therapy (P ¼ 0.004). All low-level mupirocin-resistant isolates were SCCmec type I and contained the V588F point mutation in the native tRNA synthetase gene that encodes resistance to mupirocin. Isolates collected before and after decolonization from the same patient were indistinguishable, suggestive of recolonization rather than acquisition of an MRSA strain from an exogenous source. All 150 MRSA isolates were typed using multilocus sequence typing and, although the qacA/B-positive genotypes were not recorded, there was a significant association of qacA/B genes with isolates of ST228 identified in cases compared with the controls (65 cases versus 49 controls; P ¼0.002). Lee et al. 76 acknowledged that it is difficult to separate the effects of the individual agents contributing to the failure of decolonization. The presence of qacA/B genes alone did not predict decolonization failure (P¼ 0.44) nor did low-level mupirocin resistance alone (P ¼0.32). The combination of both low-level mupirocin resistance and genotypic chlorhexidine resistance was an independent risk factor for failure of decolonization (P ¼ 0.004). As phenotypic chlorhexidine susceptibility was not measured, it is not possible to determine how many of the isolates actually had reduced susceptibility to chlorhexidine. Studies commonly do not include follow-up with chlorhexidine susceptibility testing; 83 -86 however, when investigated, an increase in reduced susceptibility to chlorhexidine following chlorhexidine use was not identified. 83 ,87
Summary of current knowledge
The biguanide antiseptic chlorhexidine was introduced into clinical practice .50 years ago, and its use is likely to continue and, indeed, increase. In reviewing the information available about this antiseptic agent and its association with staphylococci, it is apparent that there are important gaps in the current knowledge.
Firstly, the development of a standardized method for the detection of reduced susceptibility and/or resistance to in-use concentrations of chlorhexidine, along with a consensus definition of chlorhexidine 'resistance' are crucial for taking this area of research forward. Investigation of the impact of environmental factors on the development of reduced susceptibility to chlorhexidine and the frequency with which reduced susceptibility to chlorhexidine develops would then be possible. 11 The existence of subpopulations of staphylococci that are able to survive at in-use concentrations of chlorhexidine, or heterogeneous chlorhexidine resistance, is an important area of further investigation considering the effect of residual concentrations of biocides encountered in the healthcare environment. Secondly, the relationship between the carriage of chlorhexidine resistance genes, such as qacA, and phenotypic reduced chlorhexidine susceptibility is not clear. Questions relating to the transmission of resistance associated with qac genes and mobile genetic elements leading to cross-resistance and/or coresistance with antibiotics remain unanswered. In order to answer these questions, the measurement of biocide resistance gene expression in relation to phenotypically reduced susceptibility to chlorhexidine may be of benefit.
Finally, although there is no shortage of information about the in vitro susceptibility to chlorhexidine of staphylococci, information about the clinical impact of in vivo reduced susceptibility to chlorhexidine is limited. Of relevance here, the role of selection pressure for coresistance and transmission of genes needs to be examined in a way that controls for confounding. The effect of coadministered antiseptics (e.g. alcohol) and residual Review 2555 JAC concentrations on the emergence of reduced susceptibility needs to be clarified. As reviewed here, only two studies have investigated staphylococci exhibiting reduced susceptibility to chlorhexidine and/or the presence of chlorhexidine efflux-mediated resistance genes, which may be associated with clinical failure of the decolonization/treatment of staphylococci. A correlation between the occurrence of reduced chlorhexidine susceptibility and decolonization failure does not indicate causality, as there are possible confounding factors. Investigation of a correlation and causality between increased chlorhexidine use, in particular the types of use, and an increased prevalence of reduced susceptibility to chlorhexidine in staphylococci is required. Ultimately, large, multicentre studies are needed.
We anticipate that clinical use of chlorhexidine will continue to increase and it will be important to be alert to the possibility that this may lead to the emergence of new clones with reduced susceptibility. Indiscriminate chlorhexidine use in the absence of efficacy data should be discouraged.
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